<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626998</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 164/ 2022</org_study_id>
    <nct_id>NCT05626998</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Gabapentin Premedication on the Emergence Agitation After Rhinoplasty</brief_title>
  <official_title>The Effect of Intramuscular Dexmedetomidine Versus Oral Gabapentin Premedication on the Emergence Agitation After Rhinoplasty. A Prospective, Randomized, Double-blind Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of intramuscular dexmedetomidine versus oral gabapentin premedication&#xD;
      on the emergence agitation after rhinoplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emergence agitation (EA) is a clinical condition characterized by agitation, confusion,&#xD;
      disorientation, and aggressive behavior in the early phase of recovery from general&#xD;
      anesthesia (incidence about 21.3%). This may lead to various injuries, self-extubation,&#xD;
      bleeding, increased pain, removal of catheters, increased blood pressure, heart rate, and&#xD;
      myocardial oxygen consumption. Premedication with dexmedetomidine and gabapentin are&#xD;
      promising options for EA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>emergence agitation (EA)</measure>
    <time_frame>During first hour of recovery.</time_frame>
    <description>in the form of Riker Sedation-Agitation Scale (where 1 = &quot;unarousable&quot; and 7 = &quot;dangerous agitation&quot; with score ≥5 considered EA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain in the form of visual analog scale</measure>
    <time_frame>every 4 hours for 12 hours</time_frame>
    <description>(VAS, 0=no pain; 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the common adverse effects</measure>
    <time_frame>at 12 hours</time_frame>
    <description>nausea and vomiting, dizziness, and headache</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants will not receive premedication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists grade I or II.&#xD;
&#xD;
          -  Sex: Both sexes.&#xD;
&#xD;
          -  Age between 18 and 40 years.&#xD;
&#xD;
          -  Patients scheduled for rhinoplasty under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Declining to give written informed consent.&#xD;
&#xD;
          -  History of allergy to the medications used in the study.&#xD;
&#xD;
          -  history of cardiovascular diseases including bradycardia, heart block, and&#xD;
             hypertension.&#xD;
&#xD;
          -  History of chest problems including bronchial asthma.&#xD;
&#xD;
          -  Had a history of drug or alcohol abuse.&#xD;
&#xD;
          -  Taking opioids or sedative medications.&#xD;
&#xD;
          -  Inability to communicate with patients to evaluate postoperative pain.&#xD;
&#xD;
          -  Hepatic or renal failure.&#xD;
&#xD;
          -  Psychiatric disorders with antipsychotics or antidepressants.&#xD;
&#xD;
          -  Bleeding disorders, antiplatelets (aspirin, clopidogrel), or anticoagulant (warfarin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tamer S abdelaziz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine, Ain Shams University, Cairo, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>tamer S abdelaziz, MD</last_name>
    <phone>+201154601505</phone>
    <email>drtasamir@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>faculty of medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tamer SA abdelaziz, MD</last_name>
      <phone>+201154601505</phone>
      <email>drtasamir@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ismail MO Ibrahim, MD</last_name>
      <phone>00201013972871</phone>
      <email>doc_ismail_2006@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tamer SA Abdelaziz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismail MO Ibrahim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 23, 2022</last_update_submitted>
  <last_update_submitted_qc>November 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Tamer Samir Abdelsalam</investigator_full_name>
    <investigator_title>lecturer of Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

